The Syndromic Approach Using multiplex PCR technology, we set the standard for syndromic infectious disease testing.

What is Syndromic Testing? Symptoms + Signs = Syndrome

  • A symptom is a feature apparent to the patient-like a sore throat. 

  • A sign is a measurable indication of disease-like a temperature of 102° Fahrenheit

  • A syndrome is a set of signs and symptoms that characteristically occur together. 

  • Syndromic testing is the process of using one test to simultaneously target multiple pathogens with overlapping signs and symptoms. 

The BioFire® FilmArray® System performs syndromic multiplex PCR tests. Each panel targets a comprehensive grouping of pathogens that could be causing a specific syndrome-like an upper respiratory infection.

How Does Syndromic Infectious Disease Testing Work? We take a symptom-driven, molecular approach to infectious disease diagnostics.

The BioFire System utilizes multiplex polymerase chain reaction (PCR) technology—a process that simultaneously amplifies the nucleic acid of multiple targets in a single chemical reaction.

A BioFire syndromic test isolates, amplifies, and detects the DNA of microorganisms that cause overlapping signs and symptoms. The entire chemical process takes place inside a pouch, which has been engineered with an array of several individual wells on a single place. Each well includes the materials needed to amplify and identify one specific organism on the panel menu. After PCR is completed, any target present in the patient sample is identified based on which wells in the array confirm the presence or absence of nucleic acid.

The design of the BioFire® FilmArray® Panels facilitates rapid multiplex PCR while preventing cross-contamination and providing automated, user-friendly results on each target in the array.

Syndromic Testing vs. Traditional Testing Multiplex PCR is sensitive and specific.

By targeting pathogens and antimicrobial resistance genes at the molecular level, syndromic infectious disease testing from BioFire is more sensitive than culture and more efficient than a serial approach involving individual and send-out tests.

Traditionally, diagnosing a bacterial infection depends on growing the organism in culture, which can be slow and even ineffective. A syndromic PCR test can detect bacteria in a sample within hours instead of days—even if the organism is difficult to grow or nonviable.

Determining the cause of a viral infection, even if there is no specific treatment for it, can help healthcare providers avoid unnecessary antibiotics, reduce hospital length-of-stay, and improve patient satisfaction.

The BioFire System also detects parasites and fungi for relevant syndromes, which helps healthcare providers determine a causative agent sooner to avoid guesswork and downstream testing.

Additionally, identifying antimicrobial resistance genes can promote antimicrobial stewardship and facilitate more informed patient management decisions.

The BioFire® Respiratory 2.1
(RP2.1) Panel

SARS-CoV-2 is a top concern for patients and clinicians, but several respiratory pathogens can cause nearly indistinguishable symptoms. Th FDA De Novo authorized Biofire RP2.1 Panel is a frontline test to help clinicians quick) influenza, RSV, and many others.

Would you like more details on our program? Download our Provider Presentation Now.


    Viruses & Bacteria


    Improve Clinical outcomes

    The BioFire® FilmArray® Respiratory Panels has been shown to significantly reduce  ICU days  and duration of antibiotic use. Optimize patient management with clinically actionable results.

    Don't Guess. Know.

    The typical symptoms of a respiratory infection can be caused by many viruses and bacteria. Remove the guesswork with syndromic testing from BioFire. The BioFire® FilmArray® Panels combine several possible pathogens into one rapid test, with results in about an hour. BioFire’s multiplex PCR technology is more sensitive than culture and can help inform timely optimal therapy. 

    BioFire's Respiratory Solutions with SARS-CoV-2

    Biofire has brought its syndromic approach to COVID-19 testing. BioFire’s comprehensive panels provide fast , accurate results helping to inform faster treatment decisions and relieve anxious patients.

    BioFire® Respiratory 2.1 (RP2.1) Panel

    Now the first FDA De Novo authorized test for COVID-19, the BioFire RP2.1 Panel detects 22 respiratory pathogens, including SARS-CoV-2, to help clinicians quickly rule in and rule out common causes of respiratory illness in about 45 minutes. The BioFire RP2.1 Panel runs on the BioFire® FilmArray®  Torch and the BioFire® FilmArray® 2.0 2.0 Systems in laboratories certified to perform CLIA high complexity or moderate complexity tests. 

    Sample type: nasopharyngeal swab (NPS) in transport media or saline.

    SARS-CoV-2 Reactivity with BioFire Respiratory Panels

    Bioinformatics for the SARS-CoV-2 virus is expanding at a rapid rate since the emergence of the virus in human infection in late 2019. Thousands of viral whole genome sequences are being evaluated and submitted to public and private databases on a weekly basis. 

    BioFire continues to monitor these new sequences and is performing regular in silico analyses of the SARS-CoV-2 assays in the BioFire RP2.1 Panel family of products (the BioFire RP2.1 Panel, the BioFire®  Respiratory 2.1 plus Panel** , and the BioFire RP2.1-EZ Panel [EUA]) in accordance with the FDA’s policy for evaluating the impact of viral mutations on COVID-19 tests.

    Don't Guess. Know.

    SARS-CoV-2 is a top concern for patients and clinicians, but several respiratory pathogens can cause nearly indistinguishable symptoms. BioFire’s syndromic panels combine the ability to detect several of these possible pathogens into one, rapid test, taking the guesswork out of choosing which pathogens to test for. BioFire’s multiplex PCR technology is more sensitive than culture and can help inform timely optimal therapy. 


    Contact us today to schedule a consultation so we can answer any questions you may have.

    We can have you testing and treating patients in 2-3 business days.